Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

FDA Awards Fast-track Status to Sangamo’s Investigational Gene Therapy SB-525 for Hemophila A

The U.S. Food and Drug Administration (FDA) has granted fast-track status to SB-525, a clinical gene therapy for hemophilia A developed by Sangamo Therapeutics in partnership with Pfizer. SB-525 delivers a human factor VIII cDNA construct and synthetic liver-specific promoter to the cell’s nucleus by using recombinant adeno-associated virus (rAAV). The…

BDI Pharma Employees Raise Funds, Awareness on World Hemophilia Day

In recognition of the World Hemophilia Day, BDI Pharma employees company-wide united to raise awareness and money to support those affected by bleeding disorders. Events were held April 17 at the company’s South Carolina, Texas and Kansas sites, with employees joining remotely to raise money to support the WFH (World Federation of Hemophilia) by wearing…